FSD Pharma Investments Pay Off Amid Robust Expansion at Ontario Facility -- CFN Media

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"FSD Pharma Investments Pay Off Amid Robust Expansion at Ontario Facility -- CFN MediaSeattle, Washington--(Newsfile Corp. - May 8, 2019) - CFN Media Group (\"CFN Media\"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF). The company reported its fourth quarter financial results following a major year of accomplishments. Based in Cobourg, Ontario, the company's massive former Kraft Foods facility sits on 72 acres of land with nearly four million sq. ft. of expansion capacity. Management projects that the facility could generate upwards of 400 million grams of dried cannabis flower per year at full capacity.The company secured both cultivation and sales licenses for the facility earlier this year, which has opened up the door to 'robust expansion' opportunities. In partnership with tenants, like Canntab Therapeutics Ltd., the company leases manufacturing space in exchange for a royalty on sales and rights to the Canadian market. This business model limits its capital expenditures and could generate high margin revenue.The company's other partnerships include World-Class Extractions, a cannabis extraction company, and Pharmastrip Corp., a developer of cannabis-infused oral thin film strips.\"After receiving the sales license for medicinal cannabis in April 2019, we are tightly focused on developing a robust expansion plan at our Cobourg, Ontario facility under the leadership of Dr. Sara May,\" said Executive Chairman and CEO Dr. Raza Bokhari in the company's recent press release announcing its fourth quarter results. \"Finalizing the next phase of expansion, with drawings, a construction budget and timeline is our top priority.\"FSD Pharma's strategic investment portfolio valued at $18 million after a market-to-market unrealized gain of $10 million.Management remains tightly focused on 'robust expansion' plan at its Cobourg, Ontario facility under the leadership of Dr. Sara May.Balance sheet includes $22 million in cash, as of December 31, 2018, with total net assets in excess of $50 million with no long-term liabilities.New auditing firm hired ahead of listing on the New York Stock Exchange.Growing Investment PortfolioFSD Pharma recorded a $10 million unrealized gain on its strategic investmen...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B